These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT. Chappell BJ; Margot NA; Miller MD AIDS; 2007 Mar; 21(6):761-3. PubMed ID: 17413698 [TBL] [Abstract][Full Text] [Related]
8. Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen. Tamalet C; Tomei C; Henry M; Solas C; Villacian J; Colson P AIDS; 2007 Nov; 21(18):2551-2. PubMed ID: 18025898 [No Abstract] [Full Text] [Related]
9. Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations. Hsu R; Lanier ER; Rouse EG; Oie KL; Pappa KA; Ross LL Antivir Ther; 2008; 13(5):735-7. PubMed ID: 18771059 [TBL] [Abstract][Full Text] [Related]
10. The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir. Theys K; Vercauteren J; Abecasis AB; Libin P; Deforche K; Vandamme AM; Camacho R Infect Genet Evol; 2009 Jul; 9(4):683-8. PubMed ID: 19038365 [TBL] [Abstract][Full Text] [Related]
11. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients. Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827 [TBL] [Abstract][Full Text] [Related]
12. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. Miller MD; Margot N; Lu B; Zhong L; Chen SS; Cheng A; Wulfsohn M J Infect Dis; 2004 Mar; 189(5):837-46. PubMed ID: 14976601 [TBL] [Abstract][Full Text] [Related]
13. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir. de Mendoza C; Jiménez-Nacher I; Garrido C; Barreiro P; Poveda E; Corral A; Zahonero N; González-Lahoz J; Soriano V Clin Infect Dis; 2008 Jun; 46(11):1782-5. PubMed ID: 18426370 [TBL] [Abstract][Full Text] [Related]
14. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Rickenbach M; Ledergerber B; Günthard HF; Clin Infect Dis; 2008 Apr; 46(8):1299-309. PubMed ID: 18444871 [TBL] [Abstract][Full Text] [Related]
16. Comment on: High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. Parienti JJ J Antimicrob Chemother; 2009 May; 63(5):1080; author reply 1080-1. PubMed ID: 19158108 [No Abstract] [Full Text] [Related]
17. Effect of tenofovir on didanosine absorption in patients with HIV. Pecora Fulco P; Kirian MA Ann Pharmacother; 2003 Sep; 37(9):1325-8. PubMed ID: 12921517 [TBL] [Abstract][Full Text] [Related]
18. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. Brenner BG; Oliveira M; Doualla-Bell F; Moisi DD; Ntemgwa M; Frankel F; Essex M; Wainberg MA AIDS; 2006 Jun; 20(9):F9-13. PubMed ID: 16816549 [TBL] [Abstract][Full Text] [Related]
19. Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected woman. Ripamonti D; Maggiolo F; Suter F AIDS; 2007 May; 21(8):1059-60. PubMed ID: 17457107 [No Abstract] [Full Text] [Related]
20. Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs). Férir G; Vermeire K; Huskens D; Balzarini J; Van Damme EJ; Kehr JC; Dittmann E; Swanson MD; Markovitz DM; Schols D Antiviral Res; 2011 Jun; 90(3):200-4. PubMed ID: 21501631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]